| Aspartic-acid | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Aspartic-acid | hsa00100 | Steroid biosynthesis | 4.70E-02 | 1 | P35610 | SOAT1 | More | |
| Aspartic-acid | hsa00220 | Arginine biosynthesis | 2.66E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | |
| Aspartic-acid | hsa00240 | Pyrimidine metabolism | 1.57E-02 | 4 | P21589, P32320, P27707, P04183 | NT5E, CDA, DCK, TK1 | More | |
| Aspartic-acid | hsa00471 | D-Glutamine and D-glutamate metabolism | 2.41E-02 | 1 | P49448 | GLUD2 | More | |
| Aspartic-acid | hsa00500 | Starch and sucrose metabolism | 1.13E-03 | 3 | O43451, P46976, P35557 | MGAM, GYG1, GCK | More | |
| Aspartic-acid | hsa00512 | Mucin type O-glycan biosynthesis | 1.22E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | |
| Aspartic-acid | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 4.70E-02 | 1 | P35557 | GCK | More | |
| Aspartic-acid | hsa00534 | Glycosaminoglycan biosynthesis - heparan sulfate / heparin | 3.03E-02 | 1 | O14792 | HS3ST1 | More | |
| Aspartic-acid | hsa00564 | Glycerophospholipid metabolism | 1.97E-02 | 3 | P48651, Q9Y6K0, P35790 | PTDSS1, CEPT1, CHKA | More | |
| Aspartic-acid | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Aspartic-acid | hsa00670 | One carbon pool by folate | 3.95E-02 | 2 | O95954, Q99707 | FTCD, MTR | More | |
| Aspartic-acid | hsa00730 | Thiamine metabolism | 2.20E-05 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | |
| Aspartic-acid | hsa00770 | Pantothenate and CoA biosynthesis | 1.78E-02 | 2 | O95498, O95497 | VNN2, VNN1 | More | |
| Aspartic-acid | hsa01040 | Biosynthesis of unsaturated fatty acids | 4.77E-02 | 1 | O00767 | SCD | More | |
| Aspartic-acid | hsa01240 | Biosynthesis of cofactors | 3.34E-02 | 3 | P05186, Q9Y6K8, O75911 | ALPL, AK5, DHRS3 | More | |
| Aspartic-acid | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.80E-02 | 2 | P17252, Q9GZP0 | PRKCA, PDGFD | More | |
| Aspartic-acid | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | |
| Aspartic-acid | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
| Aspartic-acid | hsa03010 | Ribosome | 1.22E-02 | 2 | P46777, P50914 | RPL5, RPL14 | More | |
| Aspartic-acid | hsa03013 | RNA transport | 2.14E-03 | 11 | O14980, P61326, Q7Z3B4, P35658, P68104, Q14152, O75822, Q9Y6A5, Q14232, P51114, Q53GS7 | XPO1, MAGOH, NUP54, NUP214, EEF1A1, EIF3A, EIF3J, TACC3, EIF2B1, FXR1, GLE1 | More | |
| Aspartic-acid | hsa03050 | Proteasome | 2.42E-02 | 1 | O43242 | PSMD3 | More | |
| Aspartic-acid | hsa04010 | MAPK signaling pathway | 5.69E-03 | 4 | P17252, O95267, P09603, Q9GZP0 | PRKCA, RASGRP1, CSF1, PDGFD | More | |
| Aspartic-acid | hsa04012 | ErbB signaling pathway | 4.91E-02 | 3 | P49841, Q13191, P42338 | GSK3B, CBLB, PIK3CB | More | |
| Aspartic-acid | hsa04014 | Ras signaling pathway | 2.60E-03 | 4 | P09603, Q9GZP0, P17252, O95267 | CSF1, PDGFD, PRKCA, RASGRP1 | More | |
| Aspartic-acid | hsa04015 | Rap1 signaling pathway | 1.84E-04 | 5 | P09603, Q9GZP0, P25116, P08514, P17252 | CSF1, PDGFD, F2R, ITGA2B, PRKCA | More | |
| Aspartic-acid | hsa04020 | Calcium signaling pathway | 1.21E-02 | 3 | P17252, P25116, Q9GZP0 | PRKCA, F2R, PDGFD | More | |
| Aspartic-acid | hsa04060 | Cytokine-cytokine receptor interaction | 3.84E-02 | 8 | P14784, P27930, Q13651, Q9HBE5, P25024, P01375, P09341, Q93038 | IL2RB, IL1R2, IL10RA, IL21R, CXCR1, TNF, CXCL1, TNFRSF25 | More | |
| Aspartic-acid | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.44E-02 | 5 | P09341, P25024, Q13651, P14784, P01375 | CXCL1, CXCR1, IL10RA, IL2RB, TNF | More | |
| Aspartic-acid | hsa04064 | NF-kappa B signaling pathway | 1.68E-03 | 13 | P10415, Q13489, O00463, Q13546, P01375, Q04759, Q9UDY8, Q16548, P06239, Q8WV28, Q13315, P24522, P09341 | BCL2, BIRC3, TRAF5, RIPK1, TNF, PRKCQ, MALT1, BCL2A1, LCK, BLNK, ATM, GADD45A, CXCL1 | More | |
| Aspartic-acid | hsa04071 | Sphingolipid signaling pathway | 1.61E-02 | 6 | P17252, P21453, Q9H228, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | |
| Aspartic-acid | hsa04072 | Phospholipase D signaling pathway | 7.75E-03 | 3 | P25116, P17252, Q9GZP0 | F2R, PRKCA, PDGFD | More | |
| Aspartic-acid | hsa04080 | Neuroactive ligand-receptor interaction | 1.05E-03 | 10 | P08311, P00734, Q15722, P21453, Q9H228, O00398, Q96G91, P21462, P21730, Q16581 | CTSG, F2, LTB4R, S1PR1, EDG8, P2RY10, P2RY11, FPR1, C5AR1, C3AR1 | More | |
| Aspartic-acid | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | |
| Aspartic-acid | hsa04142 | Lysosome | 4.36E-02 | 6 | Q13488, P08311, P43234, P06280, P08962, Q9Y6Q5 | TCIRG1, CTSG, CTSO, GLA, CD63, AP1M2 | More | |
| Aspartic-acid | hsa04145 | Phagosome | 1.32E-03 | 9 | Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | |
| Aspartic-acid | hsa04151 | PI3K-Akt signaling pathway | 4.16E-03 | 5 | P25116, P09603, Q9GZP0, P08514, P17252 | F2R, CSF1, PDGFD, ITGA2B, PRKCA | More | |
| Aspartic-acid | hsa04217 | Necroptosis | 3.68E-02 | 8 | O00463, P01568, Q13489, Q13546, P06737, Q6FI13, P10415, O43633 | TRAF5, IFNA21, BIRC3, RIPK1, PYGL, H2AC18; H2AC19, BCL2, CHMP2A | More | |
| Aspartic-acid | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | |
| Aspartic-acid | hsa04350 | TGF-beta signaling pathway | 3.68E-02 | 2 | Q14766, Q15583 | LTBP1, TGIF1 | More | |
| Aspartic-acid | hsa04392 | Hippo signaling pathway - multiple species | 6.35E-03 | 1 | Q9UGP4 | LIMD1 | More | |
| Aspartic-acid | hsa04510 | Focal adhesion | 2.93E-02 | 3 | P08514, P17252, Q9GZP0 | ITGA2B, PRKCA, PDGFD | More | |
| Aspartic-acid | hsa04540 | Gap junction | 1.47E-03 | 6 | P17252, P22694, Q13509, P68371, Q9GZP0, Q14643 | PRKCA, PRKACB, TUBB3, TUBB2C, PDGFD, ITPR1 | More | |
| Aspartic-acid | hsa04610 | Complement and coagulation cascades | 2.18E-07 | 5 | P25116, P00734, P0C0L4, P05107, Q9Y279 | F2R, F2, C4A, ITGB2, VSIG4 | More | |
| Aspartic-acid | hsa04611 | Platelet activation | 4.53E-03 | 3 | P25116, O95267, P08514 | F2R, RASGRP1, ITGA2B | More | |
| Aspartic-acid | hsa04612 | Antigen processing and presentation | 3.06E-02 | 5 | P13765, P26715, P26717, P01732, P01375 | HLA-DOB, KLRC1, KLRC2, CD8A, TNF | More | |
| Aspartic-acid | hsa04613 | Neutrophil extracellular trap formation | 1.55E-02 | 12 | P17252, O60603, P05164, P08246, Q9UM07, Q6FI13, P14598, Q15080, P20160, P08311, P21730, P21462 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF1, NCF4, AZU1, CTSG, C5AR1, FPR1 | More | |
| Aspartic-acid | hsa04622 | RIG-I-like receptor signaling pathway | 1.36E-02 | 2 | Q12933, P10145 | TRAF2, IL8 | More | |
| Aspartic-acid | hsa04640 | Hematopoietic cell lineage | 6.77E-06 | 13 | P08514, P21926, P14778, P27930, P11836, P25063, P07766, P01732, P01730, P09564, P13765, P01375, P09603 | ITGA2B, CD9, IL1R1, IL1R2, MS4A1, CD24, CD3E, CD8A, CD4, CD7, HLA-DOB, TNF, CSF1 | More | |
| Aspartic-acid | hsa04650 | Natural killer cell mediated cytotoxicity | 5.50E-05 | 9 | P01375, P17252, P06239, O60880, P20963, P42338, P26718, P26717, P26715 | TNF, PRKCA, LCK, SH2D1A, CD247, PIK3CB, KLRK1, KLRC2, KLRC1 | More | |
| Aspartic-acid | hsa04658 | Th1 and Th2 cell differentiation | 6.68E-06 | 9 | Q04759, P07766, P20963, P06239, Q14765, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, LCK, STAT4, TBX21, IL2RB, HLA-DOB, RUNX3 | More | |
| Aspartic-acid | hsa04659 | Th17 cell differentiation | 4.11E-05 | 11 | Q04759, Q16539, P01730, P06239, P14784, P13765, P14778, Q9HBE5, Q9UL17, P07766, P20963 | PRKCQ, MAPK14, CD4, LCK, IL2RB, HLA-DOB, IL1R1, IL21R, TBX21, CD3E, CD247 | More | |
| Aspartic-acid | hsa04660 | T cell receptor signaling pathway | 2.88E-05 | 10 | P01375, Q04759, P42338, Q08881, P07766, P20963, P01732, Q13191, P06239, P49841 | TNF, PRKCQ, PIK3CB, ITK, CD3E, CD247, CD8A, CBLB, LCK, GSK3B | More | |
| Aspartic-acid | hsa04668 | TNF signaling pathway | 3.06E-02 | 5 | P01375, O00463, P09341, P20749, P42338 | TNF, TRAF5, CXCL1, BCL3, PIK3CB | More | |
| Aspartic-acid | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.28E-02 | 4 | P22694, P42338, P24723, Q04759 | PRKACB, PIK3CB, PRKCH, PRKCQ | More | |
| Aspartic-acid | hsa04810 | Regulation of actin cytoskeleton | 1.21E-02 | 3 | P08514, Q9GZP0, P25116 | ITGA2B, PDGFD, F2R | More | |
| Aspartic-acid | hsa04910 | Insulin signaling pathway | 1.08E-02 | 5 | P22694, P06737, P42338, P49841, Q13191 | PRKACB, PYGL, PIK3CB, GSK3B, CBLB | More | |
| Aspartic-acid | hsa04912 | GnRH signaling pathway | 4.99E-02 | 1 | P18146 | EGR1 | More | |
| Aspartic-acid | hsa04916 | Melanogenesis | 4.34E-02 | 4 | P22694, Q9UJU2, P17252, P04628 | PRKACB, LEF1, PRKCA, WNT1 | More | |
| Aspartic-acid | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.52E-02 | 5 | Q14643, P22694, P23771, P17252, P10415 | ITPR1, PRKACB, GATA3, PRKCA, BCL2 | More | |
| Aspartic-acid | hsa04931 | Insulin resistance | 7.80E-03 | 5 | P01375, P42338, P49841, Q04759, P06737 | TNF, PIK3CB, GSK3B, PRKCQ, PYGL | More | |
| Aspartic-acid | hsa04950 | Maturity onset diabetes of the young | 4.70E-02 | 1 | P35557 | GCK | More | |
| Aspartic-acid | hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 3.27E-02 | 3 | P20020, P17252, P22694 | ATP2B1, PRKCA, PRKACB | More | |
| Aspartic-acid | hsa04962 | Vasopressin-regulated water reabsorption | 4.51E-02 | 1 | Q9UJW0 | DCTN4 | More | |
| Aspartic-acid | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Aspartic-acid | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Aspartic-acid | hsa04970 | Salivary secretion | 4.34E-02 | 4 | P22694, Q14643, P20020, P17252 | PRKACB, ITPR1, ATP2B1, PRKCA | More | |
| Aspartic-acid | hsa04972 | Pancreatic secretion | 3.27E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | |
| Aspartic-acid | hsa05017 | Spinocerebellar ataxia | 4.80E-02 | 1 | O43242 | PSMD3 | More | |
| Aspartic-acid | hsa05133 | Pertussis | 8.35E-05 | 3 | P05107, P10145, P0C0L4 | ITGB2, IL8, C4A | More | |
| Aspartic-acid | hsa05135 | Yersinia infection | 1.45E-02 | 5 | P06239, P01375, P42338, P49841, P01732 | LCK, TNF, PIK3CB, GSK3B, CD8A | More | |
| Aspartic-acid | hsa05142 | Chagas disease | 3.97E-02 | 4 | P01375, P42338, P07766, P20963 | TNF, PIK3CB, CD3E, CD247 | More | |
| Aspartic-acid | hsa05143 | African trypanosomiasis | 7.35E-04 | 2 | P69905, P68871 | HBA2, HBB | More | |
| Aspartic-acid | hsa05144 | Malaria | 1.52E-06 | 8 | P60033, P69905, P68871, P01375, P05107, P35443, P10145, P26718 | CD81, HBA2, HBB, TNF, ITGB2, THBS4, IL8, KLRK1 | More | |
| Aspartic-acid | hsa05146 | Amoebiasis | 6.94E-05 | 8 | P09341, P27930, P01375, P42338, P05089, P22694, P12814, P08311 | CXCL1, IL1R2, TNF, PIK3CB, ARG1, PRKACB, ACTN1, CTSG | More | |
| Aspartic-acid | hsa05150 | Staphylococcus aureus infection | 3.50E-02 | 2 | P0C0L4, P05107 | C4A, ITGB2 | More | |
| Aspartic-acid | hsa05163 | Human cytomegalovirus infection | 4.01E-02 | 6 | P42338, P01375, P22694, P49841, Q13651, O00463 | PIK3CB, TNF, PRKACB, GSK3B, IL10RA, TRAF5 | More | |
| Aspartic-acid | hsa05169 | Epstein-Barr virus infection | 1.54E-02 | 8 | P13765, Q13547, O00463, P42338, Q13761, P01375, P07766, P20963 | HLA-DOB, HDAC1, TRAF5, PIK3CB, RUNX3, TNF, CD3E, CD247 | More | |
| Aspartic-acid | hsa05170 | Human immunodeficiency virus 1 infection | 1.37E-02 | 11 | P17252, Q13546, O00463, Q14643, P01568, O60603, Q13315, P23528, P10415, Q13619, Q9Y6Q5 | PRKCA, RIPK1, TRAF5, ITPR1, IFNA21, TLR2, ATM, CFL1, BCL2, CUL4A, AP1M2 | More | |
| Aspartic-acid | hsa05202 | Transcriptional misregulation in cancer | 1.28E-03 | 14 | Q12778, Q15532, Q13315, P41732, P14780, P14923, Q16548, Q13489, O15550, P35226, P05164, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, TSPAN7, MMP9, JUP, BCL2A1, BIRC3, UTX, BMI1, MPO, ELA2, BCL11B, GADD45A | More | |
| Aspartic-acid | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | |
| Aspartic-acid | hsa05217 | Basal cell carcinoma | 2.75E-02 | 4 | Q13635, P04628, Q9UJU2, P24522 | PTCH1, WNT1, LEF1, GADD45A | More | |
| Aspartic-acid | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | |
| Aspartic-acid | hsa05231 | Choline metabolism in cancer | 2.22E-02 | 2 | Q9GZP0, P17252 | PDGFD, PRKCA | More | |
| Aspartic-acid | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 6.63E-04 | 7 | P42338, P07766, P20963, P06239, Q04759, Q9HC35, P01730 | PIK3CB, CD3E, CD247, LCK, PRKCQ, EML4, CD4 | More | |
| Aspartic-acid | hsa05310 | Asthma | 3.36E-03 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | |
| Aspartic-acid | hsa05321 | Inflammatory bowel disease | 7.29E-04 | 5 | P01375, P13765, Q14765, Q9UL17, Q9HBE5 | TNF, HLA-DOB, STAT4, TBX21, IL21R | More | |
| Aspartic-acid | hsa05332 | Graft-versus-host disease | 2.36E-02 | 3 | P13765, P01375, P26715 | HLA-DOB, TNF, KLRC1 | More | |
| Aspartic-acid | hsa05340 | Primary immunodeficiency | 5.76E-05 | 5 | P01730, P11912, Q8WV28, P07766, P06239 | CD4, CD79A, BLNK, CD3E, LCK | More | |
| Aspartic-acid | hsa05410 | Hypertrophic cardiomyopathy | 2.60E-02 | 2 | P26012, P09493 | ITGB8, TPM1 | More | |
| Aspartic-acid | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
| Aspartic-acid | hsa05418 | Fluid shear stress and atherosclerosis | 3.77E-02 | 5 | P42338, Q14145, P10599, P01375, P27930 | PIK3CB, KEAP1, TXN, TNF, IL1R2 | More | |
